SCHEMBL3663231

SCHEMBL3663231

CCCC1(c2ccccc2)NC(=O)N(CC(=O)c2ccc(C(N)=O)cc2)C1=O

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.58
ALDH1A1 P00352 3/20 0.56
LMNA P02545 2/20 0.56
HTT P42858 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
GAA P10253 1/20 0.56
MAPT P10636 1/20 0.56
TSHR P16473 1/20 0.56
KMT2A Q03164 3/20 0.54
KDM4A O75164 1/20 0.50
CYP2C19 P33261 2/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
USP2 O75604 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3660389 0.91 HDAC6 (0.58) HDAC6ALDH1A1LMNAHTTNPSR1
SCHEMBL3663218 0.91 CYP2C19 (0.56) ALDH1A1LMNAGAATSHRKMT2A
SCHEMBL3663347 0.85 KMT2A (0.58) HDAC6ALDH1A1LMNAHTTNPSR1
SCHEMBL4121157 0.81 KMT2A (0.55) HDAC6ALDH1A1LMNAHTTNPSR1
SCHEMBL3663220 0.81 CYP2C19 (0.56) ALDH1A1LMNAGAATSHRKMT2A
SCHEMBL3659682 0.81 TDP1 (0.71) KMT2ACYP2C19CYP3A4CYP2C9TDP1
SCHEMBL12318021 0.79 CYP2C19 (0.60) HDAC6ALDH1A1LMNAGAATSHR
SCHEMBL3664165 0.79 KMT2A (0.52) HDAC6ALDH1A1LMNAHTTNPSR1
SCHEMBL3662924 0.79 KMT2A (0.51) HDAC6ALDH1A1LMNAHTTNPSR1
SCHEMBL3660786 0.78 KMT2A (0.57) HDAC6ALDH1A1LMNAHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2212314-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS Novartis AG (CH) 2010-08-04 EP disclosed
WO-2009050200-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS NOVARTIS AG (CH) 2009-04-23 WO disclosed
US-20090099243-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099243-A1 ORGANIC COMPOUNDS SLCO4C1, SLCO1B1, SLCO1B3 HDAC6 715/4885ALDH1A1 59/4885LMNA 2430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.